BioClinica®, Inc. (NASDAQ: BIOC) today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in February and March. BioClinica experts will discuss industry trends and also demonstrate its expanded suite of technology capabilities and offerings.
3rd Annual Outsourcing in Clinical Trials West Coast
|February 2-3, 2011|
|San Francisco, CA|
Robert Eberle, a BioClinica consultant, will present on “Identifying the Cost of Conducting Clinical Research and the Use of Imaging Core Labs,” on February 3, 2011 at 1:00 p.m., at this conference. Outsourcing in Clinical Trials brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.
12th Annual Clinical Trial Supply Europe
February 22-23, 2011
Ann Marie LaDue, Senior Project Manager, will speak on investigating the evolution of IVR (interactive voice response) systems through reflection on how they have changed over the last decade, on February 22, 2011 at 2:30 p.m. She will also discuss what to look for when evaluating IVR/IWR (interactive web response) technology, and how to choose a system that best matches an organization’s requirements. This conference brings together clinical supply managers to uncover essential techniques to simplify supply for clinical trials.
2nd Annual Outsourcing in Clinical Trials East Coast
|March 9-10, 2011|
|Booth # 42|
Robert Eberle, a BioClinica consultant, will present “Identifying the Cost of Conducting Clinical Research and the Use of Imaging Core Labs” on March 9, 2011 at 3:30 p.m., at this conference. Outsourcing in Clinical Trials brings together major pharma and biotech manufacturers to debate potential solutions to complex challenges. As the industry struggles to meet the challenges associated with a difficult economic climate, making the best use of available resources is more important than ever. As a leading provider of outsourced clinical trial services, BioClinica will demonstrate its efficient and cost-effective suite of clinical trial solutions.
Clinical Data Quality Summit
March 16-17, 2011
Sheraton National Hotel Arlington, VA
Jonathan Andrus, CCDM, Vice President, Data and Study Operations, will participate in a plenary session on Wednesday March 16, 2011 at 10:30 a.m. at this multidisciplinary summit that will review the case for quality in such areas as patient care, clinical records, protocol design, standards, e-clinical systems, policies and clinical data. Andrus will highlight foundational principles from a clinical, regulatory and data viewpoint.
4th Annual Forum on Clinical Trial Management Systems (CTMS)
March 24-25, 2011
BioClinica CTMS helps sponsors to leverage the power, familiarity and ubiquity of Microsoft Office and SharePoint platforms to deliver a real world window on clinical operations, across studies and across clinical technologies. Addressing this forum will be Les Jordan, CTO, Life Sciences Industry Unit at Microsoft, who will discuss how SharePoint helps companies to manage their clinical operational data by collecting more timely information and making more informed decisions. Bob Leonard of Harvard Clinical Research institute (“HCRI”) will discuss the benefits HCRI has seen from surfacing clinical operations data through SharePoint via their BioClinica CTMS system, and how they use SharePoint to connect to Microsoft Office applications for improved data visibility and control.
Partnerships in Clinical Trials
March 30-April 1, 2011
Booth # 718
BioClinica will demonstrate its expanded suite of integrated clinical trial services that maximize efficiency and manageability of the clinical trial process at this clinical operations and outsourcing event which brings nearly 2,000 of the world’s most strategic clinical trials executives to one location.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.